Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference

    Date:

    Savara Inc. SVRA (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Guggenheim Inaugural Healthcare Conference on November 12, 2024 at 10:00am PT/1:00pm ET. A live webcast and subsequent replay of the fireside chat will be available on Savara’s website at https://savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

    About Savara

    Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (X, formerly known as Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

    Market News and Data brought to you by Benzinga APIs

    Go Source

    Chart

    SignUp For Breaking Alerts

    New Graphic

    We respect your email privacy

    Share post:

    Popular

    More like this
    Related

    Satellite Images Reveal North Korea Reportedly Receiving Illicit Oil from Russia

    Satellite images have reportedly revealed that Russia has supplied...

    “I Knew If I Bought a Sink”: What Does Elon Musk’s Cryptic Tweet Mean?

    Elon Musk on Saturday shared a cryptic tweet on...

    Trump Plans DOJ Overhaul Including Firing of Jack Smith’s Team

    President-elect Donald Trump is preparing a sweeping plan to...

    Trump Picks Project 2025 Co-Author Russell Vought for OMB

    President-elect Donald Trump has selected Russell Vought, co-author of...